Janssen COVID-19 Vaccine

Registration for interest in the Sinopharm vaccine is now available. Register your interest.

What you need to know about Janssen vaccine

Developed by Janssen (Johnson & Johnson), the COVID-19 vaccine Ad26.COV2.S (Janssen) vaccine is the first single dose COVID-19 vaccine to be approved by the World Health Organisation for emergency listing.

What’s different about the Janssen vaccine?

Single dose vaccine

Only single-dose COVID-19 vaccine available

Currently the Janssen vaccine is the only single-dose COVID-19 vaccine approved by the WHO for emergency use.

Long shelf-life

Has a long shelf life of two years

While the vaccine must be stored in -20 degrees Celcius, it has a shelf life of two years.

Johnson & Johnson

Developed by Johnson & Johnson

This single-dose COVID-19 vaccine was developed by Janssen Pharmaceuticals, a pharmaceutical arm of Johnson & Johnson

Who is eligible for taking Janssen?

Individuals aged 18 years and older, with no history of anaphylaxis.

What is the recommended dosage for administration?

Single-dose administration of the Janssen vaccine with a minimal of 14 days interval for any other vaccines for health conditions.

How safe is Janssen?

Based on existing studies, 28 days after inoculation, Janssen vaccine has an efficacy of 85.4% against severe disease and hospitalisation as well as an efficacy of 66.9% against symptomatic moderate and severe COVID-19 infection